PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 101–200 of 1,001
Recent progress in Lynch syndrome and other familial colorectal cancer syndromes
Boland, P. M., Yurgelun, M. B., & Boland, C. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21448 · Cited by 188
“PD-1 is a 228-amino-acid membrane receptor protein that is induced on activated T cells through the T-cell antigen and cytokine receptors.(126) PD-1 has 2 primary ligands with distinct expression patterns.”
BackgroundCheckpoint blockade for cancer therapy: revitalizing a suppressed immune system
Pico de Coaña, Y., Choudhury, A., & Kiessling, R. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.005 · Cited by 184
Kim, M.-Y., Koh, J., Kim, S., Go, H., Jeon, Y. K., & Chung, D. H. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.016 · Cited by 186
Kim, S., Kim, M.-Y., Koh, J., Go, H., Lee, D. S., Jeon, Y. K., & Chung, D. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.013 · Cited by 184
“However, a blockade of the PD-1/PD-L1 pathway restores effector T-cell function and enhances anti-tumour immune responses in vivo [7,9].”
BackgroundCurrent issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 181
Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
Li, K., Qu, S., Chen, X., Wu, Q., & Shi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020404 · Cited by 180
“, CD8+ T cells) and binds to its ligand PD-L1, which is expressed on multiple malignant cells [128,129].”
BackgroundMechanism of Action of Immunotherapy
Disis, M. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.004 · Cited by 175
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
Asano, T., Meguri, Y., Yoshioka, T., Kishi, Y., Iwamoto, M., Nakamura, M., Sando, Y., Yagita, H., Koreth, J., Kim, H. T., et al. (2017) · Blood · doi:10.1182/blood-2016-09-741629 · Cited by 176
“Functional deficiency of PD1 has been reported in a variety of human autoimmune diseases including systemic lupus erythematosis, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, and recent studies have suggested that single nucleotide polymorphisms in human PD-1 genes are associated with autoimmune disea…”
BackgroundUnderstanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation
Mizuno, R., Sugiura, D., Shimizu, K., Maruhashi, T., Watada, M., Okazaki, I.-M., & Okazaki, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00630 · Cited by 171
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Kudo, M. (2018) · Cancers · doi:10.3390/cancers10110412 · Cited by 172
“The PD-1 ligands PD-L1 and PD-L2 were also discovered in 2000 [47].”
BackgroundMerelli, B., Massi, D., Cattaneo, L., & Mandalà, M. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.002 · Cited by 170
Youngblood, B., Noto, A., Porichis, F., Akondy, R. S., Ndhlovu, Z. M., Austin, J. W., Bordi, R., Procopio, F. A., Miura, T., Allen, T. M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203161 · Cited by 171
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Eun, Y., Kim, I. Y., Sun, J.-M., Lee, J., Cha, H.-S., Koh, E.-M., Kim, H., & Lee, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50574-6 · Cited by 171
Cierna, Z., Mego, M., Miskovska, V., Machalekova, K., Chovanec, M., Svetlovska, D., Hainova, K., Rejlekova, K., Macak, D., Spanik, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv574 · Cited by 162
“PD-L1 is expressed also on various tumor cells [8].”
BackgroundInfluentialKim, S., Koh, J., Kim, M.-Y., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.007 · Cited by 167
Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity
Sun, L., Li, C.-W., Chung, E. M., Yang, R., Kim, Y.-S., Park, A. H., Lai, Y.-J., Yang, Y., Wang, Y.-H., Liu, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3133 · Cited by 166
“The engagement of PD-1 with its ligand programmed death 1 ligand 1 (PD-L1), expressed on the surface of cancer cells, leads to T-cell exhaustion and immunosuppression (3).”
BackgroundA Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
Lai, W.-Y., Huang, B.-T., Wang, J.-W., Lin, P.-Y., & Yang, P.-C. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.102 · Cited by 166
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., Listì, A., Cicero, G., Rolfo, C., Santini, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7582 · Cited by 165
“An improved understanding of cancer immunology has led to the development of several MoAbs which are able to revert a non-efficient or suppressed immune-response by the blockade of the PD-1/PD-L1 axis [15, 16].”
BackgroundTargeting Immune Cell Checkpoints during Sepsis
Patil, N., Guo, Y., Luan, L., & Sherwood, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112413 · Cited by 162
“Pre-clinical studies in mice have shown that PD-1 deficiency causes an increased incidence of autoimmune pathologies such as lupus like syndromes, de novo type 1 diabetes, dilated cardiomyopathy and others [83,84].”
BackgroundRapid PD-L1 detection in tumors with PET using a highly specific peptide
Chatterjee, S., Lesniak, W. G., Miller, M. S., Lisok, A., Sikorska, E., Wharram, B., Kumar, D., Gabrielson, M., Pomper, M. G., Gabelli, S. B., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.156 · Cited by 163
“Increased PD-L1 in the tumor microenvironment (TME) causes immune suppression by deactivation of immune infiltrates via binding to programmed cell death protein 1 (PD-1) receptor, expressed by active immune infiltrates [1, 4].”
BackgroundImmunotherapy: A promising approach to reverse sepsis-induced immunosuppression
Patil, N. K., Bohannon, J. K., & Sherwood, E. R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.019 · Cited by 161
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Okiyama, N., & Tanaka, R. (2022) · Allergology International · doi:10.1016/j.alit.2022.01.001 · Cited by 159
Kurimoto, C., Inaba, H., Ariyasu, H., Iwakura, H., Ueda, Y., Uraki, S., Takeshima, K., Furukawa, Y., Morita, S., Yamamoto, Y., et al. (2020) · Cancer Science · doi:10.1111/cas.14363 · Cited by 160
Koh, J., Go, H., Keam, B., Kim, M.-Y., Nam, S. J., Kim, T. M., Lee, S.-H., Min, H. S., Kim, Y. T., Kim, D.-W., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.63 · Cited by 160
Nagato, T., Ohkuri, T., Ohara, K., Hirata, Y., Kishibe, K., Komabayashi, Y., Ueda, S., Takahara, M., Kumai, T., Ishibashi, K., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1987-x · Cited by 160
Li, W., Wu, F., Zhao, S., Shi, P., Wang, S., & Cui, D. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.004 · Cited by 158
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity
Jia, L., Xi, Q., Wang, H., Zhang, Z., Liu, H., Cheng, Y., Guo, X., Zhang, J., Zhang, Q., Zhang, L., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.074 · Cited by 159
Quatrini, L., Mariotti, F. R., Munari, E., Tumino, N., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12113285 · Cited by 158
“PD-1 specifically binds the type I transmembrane proteins PD-L1 (B7-H1; CD274) [16,17] and PD-L2 (B7-DC; CD273) [18,19], both of which are B7 family members [20,21].”
BackgroundExpression and function of PD‐1 in human γδ T cells that recognize phosphoantigens
Iwasaki, M., Tanaka, Y., Kobayashi, H., Murata‐Hirai, K., Miyabe, H., Sugie, T., Toi, M., & Minato, N. (2011) · European Journal of Immunology · doi:10.1002/eji.201040959 · Cited by 158
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
Shimoji, M., Shimizu, S., Sato, K., Suda, K., Kobayashi, Y., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.021 · Cited by 158
“PD-1 is expressed ainly on T-cells, while its ligands, PD-L1 and PD-L2, are expressed n the surface of various cells, including normal lymphoid cells nd non-lymphoid cells [1].”
BackgroundInfluentialImmunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells
Banas, R. A., Trumpower, C., Bentlejewski, C., Marshall, V., Sing, G., & Zeevi, A. (2008) · Human Immunology · doi:10.1016/j.humimm.2008.04.007 · Cited by 158
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 165
Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds
Sivanandam, V., LaRocca, C. J., Chen, N. G., Fong, Y., & Warner, S. G. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.04.003 · Cited by 176
Kwon, D., Kim, S., Kim, P., Go, H., Nam, S. J., Paik, J. H., Kim, Y. A., Kim, T. M., Heo, D. S., Kim, C. W., et al. (2015) · Histopathology · doi:10.1111/his.12882 · Cited by 161
“PD-1 is expressed mainly by activated T cells, B cells and natural killer cells, while PD-L1 is expressed by immune cells (including macrophages, dendritic cells and lymphocytes) and non-immune cells (including tumour cells).(4,6) Upon ligation by PDL1, PD-1 attenuates T cell proliferation and function, leading to T c…”
BackgroundImmune checkpoint inhibition in ovarian cancer
Hamanishi, J., Mandai, M., & Konishi, I. (2016) · International Immunology · doi:10.1093/intimm/dxw020 · Cited by 154
Koh, J., Jang, J.-Y., Keam, B., Kim, S., Kim, M.-Y., Go, H., Kim, T. M., Kim, D.-W., Kim, C.-W., Jeon, Y. K., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1108514 · Cited by 152
“PD-1 is expressed on immune cells, particularly in activated T cells, while PD-L1 and PD-L2 are expressed on antigen-presenting cells and non-immune cells in peripheral tissues.(10) Engagement of PD-1 by PD-Ls suppresses T-cell proliferation and function by inducing T-cell apoptosis, anergy, exhaustion, and the produc…”
BackgroundProgress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Lin, X., Lu, X., Luo, G., & Xiang, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111876 · Cited by 160
Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects
Liu, Z., Liu, X., Liang, J., Liu, Y., Hou, X., Zhang, M., Li, Y., & Jiang, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765101 · Cited by 151
Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options
Velu, V., Shetty, R. D., Larsson, M., & Shankar, E. M. (2015) · Retrovirology · doi:10.1186/s12977-015-0144-x · Cited by 171
“PD-1 was identified as a gene up-regulated in a T-cell hybridoma undergoing apoptotic cell death, and was thus named programmed death 1 [5,6].”
Autocrine Adenosine Signaling Promotes Regulatory T Cell–Mediated Renal Protection
Kinsey, G. R., Huang, L., Jaworska, K., Khutsishvili, K., Becker, D. A., Ye, H., Lobo, P. I., & Okusa, M. D. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010070 · Cited by 150
Hobo, W. A., Maas, F., Adisty, N., de Witte, T., Schaap, N. P., van der Voort, R., & Dolstra, H. (2010) · Blood · doi:10.1182/blood-2010-04-278739 · Cited by 167
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
Lee, L., Gupta, M., & Sahasranaman, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.591 · Cited by 148
Chronically inflamed livers up-regulate expression of inhibitory B7 family members #
Kassel, R., Cruise, M. W., Iezzoni, J. C., Taylor, N. A., Pruett, T. L., & Hahn, Y. S. (2009) · Hepatology · doi:10.1002/hep.23173 · Cited by 148
Shao, R., Fang, Y., Yu, H., Zhao, L., Jiang, Z., & Li, C.-S. (2016) · Critical Care · doi:10.1186/s13054-016-1301-x · Cited by 148
“The PD-1/PD-L1 pathway exerts inhibitory effects by regulating T-cell activation, tolerance, and immunopathology [12, 13].”
BackgroundLi, Y., Li, F., Jiang, F., Lv, X., Zhang, R., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071151 · Cited by 182
“After binding of PD-L1 or PD-L2, the recruitment of tyrosine phosphatases will begin and then generates an inhibitory signal blocking the downstream effects of PI3K/Akt pathway leading to cell cycle arrest and suppressed T-cell activation [10,25].”
BackgroundImmune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
“It was predicted that PD-1/PD-L1 blockade would have a greater anticancer effect than CTLA-4 inhibitors with fewer unwanted side effects due to the selective immunosuppressive signals delivered by cancer cells([2,20]).”
BackgroundRole of PD-1 in regulating acute infections
Brown, K. E., Freeman, G. J., Wherry, E. J., & Sharpe, A. H. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.03.007 · Cited by 147
Lugowska, I. A., Teterycz, P., & Rutkowski, P. L. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73889 · Cited by 171
“The first agents of FDA-approved immunotherapies in metastatic/unresectable cutaneous melanomas, which are accountable for the vast majority of deaths caused by skin cancers, include anti-PD-1 drugs (nivolumab, pembrolizumab) and anti-CTLA-4 antibody ipilimumab.”
BackgroundInfluentialOsum, K. C., Burrack, A. L., Martinov, T., Sahli, N. L., Mitchell, J. S., Tucker, C. G., Pauken, K. E., Papas, K., Appakalai, B., Spanier, J. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26471-9 · Cited by 147
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma
Langhans, B., Nischalke, H. D., Krämer, B., Dold, L., Lutz, P. L., Mohr, R. U., Vogt, A., Toma, M. I., Eis‐Hübinger, A. M., Nattermann, J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02427-4 · Cited by 156
Zhao, R., Song, Y., Wang, Y., Huang, Y., Li, Z., Cui, Y., Yi, M., Xia, L., Zhuang, W., Wu, X., et al. (2019) · Cell Proliferation · doi:10.1111/cpr.12571 · Cited by 161
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
Mandlik, D. S., Mandlik, S. K., & Choudhary, H. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.1054 · Cited by 158
Amniotic membrane-derived stem cells: immunomodulatory properties and potential clinical application
Insausti, C., Blanquer, M., García, A., Castellanos, G., & Moraleda, J. M. (2014) · Stem Cells and Cloning: Advances and Applications · doi:10.2147/sccaa.s58696 · Cited by 139
“They neither express the programmed cell death receptor 1 (PD1) (an inhibitory receptor that is normally expressed on activated T and B cells), nor its two ligands: programmed death ligands 1 and 2 (PD-L1 and PD-L2).(15,16,23) These two are typically upregulated by stimulation with IFN-γ.”
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 139
“Moreover, because PD-L1 expression is frequently upregulated in cancers and tumor-infiltrating lymphocytes (TILs) can express high levels of PD-1 (4, 13), PD-1 inhibits T cell responses in the tumor.”
BackgroundThe role of the adaptive immune system in regulation of gut microbiota
Kato, L. M., Kawamoto, S., Maruya, M., & Fagarasan, S. (2014) · Immunological Reviews · doi:10.1111/imr.12185 · Cited by 138
Hams, E., McCarron, M. J., Amu, S., Yagita∥, H., Azuma, M., Chen, L., & Fallon, P. G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003161 · Cited by 149
“(46), they highlight the need to consider the potential expansion of the TFH cell response and the impact on the heightened Ab response on clinical outcome.”
BackgroundDeep learning for in vivo near-infrared imaging
Ma, Z., Wang, F., Wang, W., Zhong, Y., & Dai, H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021446118 · Cited by 135
“Immunotherapy based on checkpoint blockade of the programmed cell death protein-1 (PD-1) or its ligand PD-L1 has shown great promise for treating cancer in clinics (47, 48).”
BackgroundImmunotherapy earns its spot in the ranks of cancer therapy
Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 146
“Although PD-1 is also expressed on B cells and natural killer (NK) cells, its major inhibitory functions have been elucidated in the context of T cell responses (Linsley et al., 1990, 1991; Ishida et al., 1992; Greenwald et al., 2005; Okazaki and Honjo, 2007).”
BackgroundFriend, B. D., Venick, R. S., McDiarmid, S. V., Zhou, X., Naini, B., Wang, H., Farmer, D. G., Busuttil, R. W., & Federman, N. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26682 · Cited by 135
Kitazono, S., Fujiwara, Y., Tsuta, K., Utsumi, H., Kanda, S., Horinouchi, H., Nokihara, H., Yamamoto, N., Sasada, S., WATANABE, S.-I. J., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.03.008 · Cited by 146
Obeid, J. M., Erdag, G., Smolkin, M. E., Deacon, D. H., Patterson, J. W., Chen, L., Bullock, T. N., & Slingluff, C. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1235107 · Cited by 129
“However, ligation of PD-1 can induce programmed cell death in lymphocytes.(7,10,11) or it may induce downregulation of T-cell function.”
BackgroundUpregulation of PD-L1 in Senescence and Aging
Onorati, A., Havas, A. P., Lin, B., Rajagopal, J., Sen, P., Adams, P. D., & Dou, Z. (2022) · Molecular and Cellular Biology · doi:10.1128/mcb.00171-22 · Cited by 129
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Millet, A., Martin, A. R., Ronco, C., Rocchi, S., & Benhida, R. (2016) · Medicinal Research Reviews · doi:10.1002/med.21404 · Cited by 142
Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 153
Yang, W., Chen, P. W., Li, H., Alizadeh, H., & Niederkorn, J. Y. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1606 · Cited by 125
“PD-L1 is a type 1 transmembrane glycoprotein belonging to the B7 family.17–20 Its receptor, PD-1, is a transmembrane protein belonging to the Ig superfamily that lacks the relevant motif for binding to B7-1 and B7-2.”
BackgroundSystemic Therapy for Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2017) · Oncology · doi:10.1159/000481244 · Cited by 134
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Hamid, O., & Carvajal, R. D. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.770836 · Cited by 132
“PD-1 pathway signaling functions to maintain central and peripheral tolerance [10-12], abrogate the development of autoimmunity [13,14], and minimize damage to healthy tissue during infection [12,15].”
BackgroundA case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
Carlos, G., Anforth, R. M., Chou, S., Clements, A., & Fernández‐Peñas, P. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000155 · Cited by 122
Role of PD-L1 and PD-L2 in allergic diseases and asthma
Singh, A. K., Stock, P., & Akbari, O. (2010) · Allergy · doi:10.1111/j.1398-9995.2010.02458.x · Cited by 128
“The PD-1 receptor ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) belong to the B7:CD28 family of ligands (34).”
BackgroundTsutsumi, S., Saeki, H., Nakashima, Y., Ito, S., Oki, E., Morita, M., Oda, Y., Okano, S., & Maehara, Y. (2017) · Cancer Science · doi:10.1111/cas.13237 · Cited by 121
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
Yao, Y., Wang, J., Liu, Y., Qu, Y., Wang, K., Zhang, Y., Chang, Y., Yang, Z., Wan, J., Liu, J., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00938-7 · Cited by 120
Anderson, E. S., Postow, M. A., Wolchok, J. D., Young, R. J., Ballangrud, Å., Chan, T. A.-T., Yamada, Y. J., & Beal, K. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0282-x · Cited by 124
Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions
Batus, M., Waheed, S., Ruby, C. E., Petersen, L. F., Bines, S. D., & Kaufman, H. L. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0025-9 · Cited by 132
“In preclinical animal models, antibodies that block PD-1 resuscitated melanoma-specific T-cell responses and augmented tumor regression [98–100].”
BackgroundWang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 124
Torino, F., Barnabei, A., Paragliola, R. M., Marchetti, P., Salvatori, R., & Corsello, S. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0434 · Cited by 117
PD-L2 is expressed on activated human T cells and regulates their function
Messal, N., Serriari, N.-E., Pastor, S., Nunès, J. A., & Olive, D. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.06.436 · Cited by 116
“More recently, PD-L2 expression has been detected on resting peritoneal B1 cells (Kaku and Rothstein, 2010) and in solid tumors such as ovarian carcinoma (Okazaki and Honjo, 2007).”
BackgroundHuang, W., Ran, R., Shao, B., & Li, H. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05371-0 · Cited by 120
“The binding of PD-L1 to its receptor, programmed death 1 (PD-1), could regulate T-cell activity and maintain immune tolerance of self-antigens [3].”
BackgroundKantekure, K., Yang, Y., Raghunath, P. N., Schaffer, A., Woetmann, A., Zhang, Q., Ødum, N., & Wasik, M. A. (2011) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e31821c35cb · Cited by 112
Rosato, R. R., Dávila-González, D., Choi, D. S., Qian, W., Chen, W., Kozielski, A. J., Wong, H., Dave, B., & Chang, J. C. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1037-4 · Cited by 112
Harrington, K. J., Kong, A. H., Mach, N., Chesney, J. A., Fernández, B. C., Rischin, D., Cohen, E. E. W., Radcliffe, H.-S., Gümüşçü, B., Cheng, J. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1170 · Cited by 119
“Excessive expression of PD-L1 or PD-L2 on tumor or stromal cells can result in immune evasion, leading to recurrence andmetastasis of the tumor (7).”
BackgroundCutaneous manifestations associated with immune checkpoint inhibitors
Watanabe, T., & Yamaguchi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1071983 · Cited by 129
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Kong, X., Zhang, J., Chen, S., Wang, X., Xi, Q., Shen, H., & Zhang, R. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2024.0055 · Cited by 204
Ho, T. T. B., Nasti, A., Seki, A., Komura, T., Inui, H., Kozaka, T., Kitamura, Y., Shiba, K., Yamashita, T., Yamashita, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001367 · Cited by 112
Immune escape mechanisms of intraocular tumors
Niederkorn, J. Y. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.06.002 · Cited by 121
“PD-L2 expression appears to be limited to antigen presenting cells such as macrophages and dendritic cells (Latchman et al., 2001; Okazaki and Honjo, 2007).”
BackgroundInfluentialLu, M. S., Zhang, P., Zhang, Y., Li, Z., Gong, J., Li, J., Li, J., Li, Y., Zhang, X., Lü, Z., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4000 · Cited by 120
“While PD-1 pathway is crucial for the induction and maintenance of peripheral tolerance, upregulation of PD-L1 in the tumor microenvironment leads to suppression of immune response in many solid tumors (10, 11).”
BackgroundWang, Z., Li, M. Y., Zhang, Z. H., Zuo, H. X., Wang, J. Y., Xing, Y., Ri, M., Jin, H. L., Jin, C. H., Xu, G. H., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104727 · Cited by 115
Recent Advances in Immunotherapy for Hepatocellular Carcinoma
Nakano, S., Eso, Y., Okada, H., Takai, A., Takahashi, K., & Seno, H. (2020) · Cancers · doi:10.3390/cancers12040775 · Cited by 118
“The engagement of PD-1 by its ligand PD-L1 leads to the transmission of suppressive signals into T cells and the induction of peripheral tolerance [26].”
BackgroundThe Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
Qiao, X., Jiang, J. D., Pang, X., Huang, M.-C., Tang, Y.-J., Liang, X., & Tang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01721 · Cited by 136
Common germline variants of the human APOE gene modulate melanoma progression and survival
Ostendorf, B. N., Bilanovic, J., Adaku, N., Tafreshian, K. N., Tavora, B., Vaughan, R. D., & Tavazoie, S. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0879-3 · Cited by 108
Lounder, D. T., Bin, Q., de Min, C., & Jordan, M. B. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018025858 · Cited by 113
Germline genetic determination of cancer progression and survival
Ostendorf, B. N., Tafreshian, K. N., Adaku, N., Bilanovic, J., Tavora, B., & Tavazoie, S. F. (2019) · doi:10.1101/576181 · Cited by 108
Biliary tract cancers: current knowledge, clinical candidates and future challenges
Tariq, N.-U.-A., McNamara, M. G., & Valle, J. W. (2019) · Cancer Management and Research · doi:10.2147/cmar.s157092 · Cited by 120
“Immune check point inhibitors are currently being used across various poor prognostic tumor groups with good results; however, there is some association of programmed cell death protein ligand-1 (PD-L1), expression and effectiveness of these treatments.(127,128) Expression of PD-L1 in BTC shows a wide range from 29% t…”
BackgroundImmune checkpoints in central nervous system autoimmunity
Joller, N., Peters, A., Anderson, A. C., & Kuchroo, V. K. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01136.x · Cited by 106
“In humans, PD-1 polymorphisms have been associated with a number of autoimmune diseases, including MS (183).”
BackgroundLucas, J., Hsieh, T., Halicka, H. D., Darżynkiewicz, Z., & WU, J. M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4512 · Cited by 141
“Programmed cell death ligand 1 (PD-L1) is a functional ligand of programmed cell death 1 (PD-1) (1).”
BackgroundInfluentialNishida, M., Yamashita, N., Ogawa, T., Koseki, K., Warabi, E., Ohue, T., Komatsu, M., Matsushita, H., Kakimi, K., Kawakami, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002954 · Cited by 117
Wu, Y., Sun, X., Kang, K., Yang, Y., Li, H., Zhao, A., & Niu, T. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01621-x · Cited by 130
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Botti, G., Fratangelo, F., Cerrone, M., Liguori, G., Cantile, M., Anniciello, A. M., Scala, S., D’Alterio, C., Trimarco, C., Ianaro, A., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1150-7 · Cited by 104
“Interaction of PD-1 with PD-L1 (B7-H1) or PD-L2 (B7-DC) represents one of the major mechanisms of tumor immune escape [13].”
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.